Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs

被引:10
|
作者
Zhang, YQ [1 ]
Coogan, PF
Palmer, JR
Strom, BL
Rosenberg, L
机构
[1] Boston Univ, Sch Med, Clin Epidemiol Res & Training Unit, Boston, MA 02118 USA
[2] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA
[3] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Div Gen Internal Med, Dept Med, Philadelphia, PA 19104 USA
来源
CANCER DETECTION AND PREVENTION | 2006年 / 30卷 / 01期
关键词
non-Hodgkin lymphoma; non-steroidal anti-inflammatory drug; case-control studies; risk factors;
D O I
10.1016/j.cdp.2005.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Risk factors for non-Hodgkin lymphoma (NHL) are largely unknown. Several studies have examined the relation of nonsteroidal anti-inflammatory drug (NSAID) use to the risk of NHL, with inconsistent results. Methods: We examined NSAID use among 529 newly diagnosed NHL cases and 2013 controls interviewed from 1977 to 2002 in our Case-Control Surveillance Study. Results: The odds ratio for NHL among subjects whose regular NSAID use began at least one year prior to hospital admission compared to never users was 0.9 (95% confidence interval (CI): 0.6-1.3). Odds ratios for less than five years, five to less than 10 years, and 10 or more years of regular use were 1.2 (95% CI: 0.8-1.9), 1.0 (95% CI: 0.5-2.1), and 0.4 (95% CI: 0.1-1.0), respectively. The results were similar for regular aspirin use. Conclusion: Our results add to the body of data suggesting that NSAIDs do not increase the risk of NHL and even suggest the possibility of protection by long-term use. (c) 2006 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:99 / 101
页数:3
相关论文
共 50 条
  • [31] Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism
    Biere-Rafi, Sara
    Di Nisio, Marcello
    Gerdes, Victor
    Porreca, Ettore
    Souverein, Patrick
    de Boer, Anthonius
    Buller, Harry
    Kamphuisen, Pieter
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (06) : 635 - 642
  • [32] Non-steroidal anti-inflammatory drugs and cardiovascular risk: At crossroads
    Farkouh, Michael E.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (08) : 736 - 737
  • [33] Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs and Risk of Non-Hodgkin Lymphoma
    Teras, Lauren R.
    Gapstur, Susan M.
    Patel, Alpa V.
    Thun, Michael J.
    Diver, W. Ryan
    Zhai, Yusheng
    Jacobs, Eric J.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2013, 22 (03) : 422 - 428
  • [34] Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk
    Hermann, M
    Ruschitzka, F
    INTERNAL MEDICINE JOURNAL, 2006, 36 (05) : 308 - U5
  • [35] Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk
    Woodruff, T.
    INTERNAL MEDICINE JOURNAL, 2006, 36 (12) : 797 - U8
  • [36] SHOULD WE USE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    HASLOCK, I
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1988, 2 : 1 - 8
  • [37] Non-steroidal anti-inflammatory drugs use and micronutrient status
    Albalawi, Omar M.
    Almarshad, Abdulrahman
    Alrwisan, Adel A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 585 - 586
  • [38] The use of non-steroidal anti-inflammatory drugs in subacute thyroiditis
    Mackenzie, FD
    Lepre, F
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (09) : 481 - 482
  • [39] RATIONAL USE OF NEW NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    FRITZ, WL
    PAXINOS, J
    GALL, EP
    DRUG THERAPY, 1978, 8 (05) : 36 - &
  • [40] INDISCRIMINATE USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS BY THE ELDERLY
    Andrade, Gabriela Barreto
    Andrade, Tamires Barreto
    da Silva, Jucelia Nunes
    REVISTA CIENTIFICA DA FACULDADE DE EDUCACAO E MEIO AMBIENTE, 2022, 13 (01): : 59 - 76